CytoSorbents Corporation (CTSO)

[pharmeng]

BMA

How do you think they will continue to approach sepsis? Are they backing off from running a pivotal trial at this time? My inclination is that if they were to run a trial with high cytokine levels as the biomarker, they would have success. They could also attract attention from pharmaceuticals to partner the filter with a sepsis drug.

I worry because the dosing study does not seem like it will give definitive results, given that the dosing study population so far (N=28) is more sick than the previous control arm. I agree that real clinical results is the main thing that will move this stock, or a partner to take over one of the indications.

At this point, people are arguing over if sales will be $700k or $900k, which in the grand scheme of things is extremely insignificant if you are hoping for this to be a billion dollar company. With real results, sales will not start at $200k and ramp up 20-50% per quarter, but should start in the tens of millions and ramp up from there once manufacturing is expanded.

Appreciate your insights, especially on the financial aspects.